Monitor the webinar replay for any disclosed partnership agreements, customer traction metrics, or revenue guidance for OMAI. The platform's commercial adoption trajectory is the key catalyst to watch.
Price Chart
Executive Summary
Lantern Pharma filed an 8-K to announce a live webinar on September 23, 2026, presenting the growth plan for its Open-Medicine AI (OMAI) multi-agentic AI drug development platform. The webinar covers market opportunity, customer feedback, platform roadmap, economics, benchmarks, and partnerships. No financial data, guidance, or material business developments were disclosed.
Key Facts
- Webinar scheduled for September 23, 2026 at 12:30 PM ET to discuss Open-Medicine AI platform
- OMAI is a wholly owned subsidiary of Lantern Pharma, first commercialized as withZeta.ai in April 2026
- ZetaOmics computational biology module released to early-access users in July 2026
- Platform available via subscription and enterprise licensing model
- CEO Panna Sharma, Chief Scientific Officer, and Principal Architect will present
Financial Impact
No financial figures disclosed; webinar is a marketing and investor relations event
Risk Factors
- OMAI commercialization may not generate anticipated revenue or achieve expected market adoption
- No drug product based on Lantern's AI platforms has received FDA marketing approval
- Partnership discussions may not result in definitive agreements
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043808 |
| Exhibit: ex99-1.htm | 0001493152-26-043808 |
| Document: 0001493152-26-043808-index-headers.html | 0001493152-26-043808 |
| Document: 0001493152-26-043808-index.html | 0001493152-26-043808 |
| Document: 0001493152-26-043808.txt | 0001493152-26-043808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6123 (+6.72%) |
Oct 13, 2026 14d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6123 (−13.85%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6123 (+28.81%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6123 (+38.77%) |
Sep 30, 2026 27d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6123 (+39.38%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6123 (−49.40%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6123 (−55.95%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6123 (−76.89%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6123 (+84.22%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6123 (−79.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers